DTRMWXHS-12

DTRMWXHS-12 is a selective, irreversible small molecule inhibitor of Bruton tyrosine kinase (BTK), developed by Zhejiang DTRM Biopharma. It is being investigated primarily for the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma, non-Hodgkin's lymphoma, and mantle cell lymphoma. The drug has also been studied in combination regimens with everolimus and pomalidomide to enhance antitumor activity and address acquired drug resistance. Preclinical studies demonstrated potent BTK inhibition with an IC50 of 0.7 nM and favorable selectivity over other kinases[3][7]. Clinical trials have evaluated its safety, tolerability, pharmacokinetics, and preliminary efficacy as both monotherapy and in combination therapies[1][6].